Fewer than one in 10 individuals eligible to benefit from weight-loss injections including Wegovy are able to get them, caution the World Health Organization as it issues its initial guidance on the therapies.
Given over a billion individuals worldwide now living with obesity, it is calling for more widespread and fairer access to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"The new guidance acknowledges that excess weight is a lifelong illness that can be treated with holistic and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are significant hurdles to universal access to the treatments that can aid individuals in losing substantial weight, says the body.
Weight-Loss Drug Supply Crisis
Even in the present best projected scenario, the manufacturing of these medications would only suffice for around 100 million people – fewer than 10% of eligible patients, according to the health organization.
The guideline calls on governments and firms to increase access, via measures like patent sharing.
Exclusive production rights on the active ingredient – the primary component of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026.
The Way Weight-Loss Jabs Work
The injections mimick a biological compound to reduce digestion speed, reduce hunger and enhance satiety so individuals consume fewer calories.
Individuals commonly start to lose weight in the initial weeks of beginning the once-weekly jabs.
Evidence suggests users may regain a significant portion within a year of halting the treatment, because their normal hunger resume.
To be overweight or obese elevates your chance for developing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight impacts people in all nations and was responsible for 3.7 million deaths worldwide in 2024, as per the health agency.
